TY  - JOUR
T1  - İmmunkompetan Yaşlı Hastada Gelişen Herpes Zoster Oftalmikus: Olgu  Sunumu
TT  - Herpes Zoster Ophthalmicus In An Immunocompetent Elderly Patient: Case  Report
AU  - Alkan Çeviker, Sevil
AU  - Günal, Özgür
AU  - Kılıç, Süleyman Sırrı
AU  - Köksal, Eda
AU  - Aygün, Cemanur
PY  - 2019
DA  - August
Y2  - 2019
JF  - Medical Journal of Western Black Sea
JO  - Med J West Black Sea
PB  - Zonguldak Bülent Ecevit Üniversitesi
WT  - DergiPark
SN  - 2822-4302
SP  - 61
EP  - 65
VL  - 3
IS  - 2
LA  - tr
AB  - Herpes zoster enfeksiyonları, immunsupresif bireyler ile 45 yaşüstündekilerde daha sık görülür. Tüm Herpes zoster vakalarının%10-20’sini Herpes Zoster Oftalmikus vakaları oluşturur. HerpesZoster Oftalmikus’un körlüğün önemli nedenlerinden biri olduğubildirilmektedir. Herpes Zoster Oftalmikus tanılı olgumuz, bilinenimmunsupresyonu olmayan risk faktörü olarak sadece ileri yaşı olanhasta olup, bu durum oldukça nadir görülmektedir. Sunulan bu olguile; Herpes Zoster Oftalmikus hastalığının erken tanısı ve topikaltedaviye ilaveten sistemik antiviral tedavi ile kalıcı görme kaybınıönlenebileceğini vurgulamayı amaçladık.
KW  - Herpes Zoster
KW  - Herpes Zoster Oftalmikus
KW  - İmmunkompetan yaşlı  hasta.
N2  - Herpes zoster infections are more common in immunosuppressiveindividuals and those over 45 years of age. 10-20% of all Herpeszoster cases are Herpes Zoster Ophthalmicus cases. Herpes ZosterOphthalmicus is reported to be one of the major causes of blindness.Our patient with herpes zoster ophthalmicus is a patient withadvanced age as a risk factor without known immunosuppression andthis is very rare. In this case report, we aimed to emphasize that earlydiagnosis of Herpes Zoster Ophthalmicus disease and systemicantiviral treatment in addition to topical treatment can preventpermanent visual loss
CR  - 1. Topçu W. A., Söyletir G. ve Doğanay M. 
Enfeksiyon Hastalıkları ve Mikrobiyolojisi. 4.baskı. 
Nobel Tıp Kitabevleri. 2017: 1474-1478.
CR  - 2. Liesegang TJ. Herpes zoster ophthalmicus natural 
history, risk factors, clinical presentation, and 
morbidity. Ophthalmology. 2008; 115: 3–12.
CR  - 3. Marra F., Chong M. and Najafzadeh M. Increasing 
incidence associated with herpes zoster infection in 
British Columbia, Canada. BMC Infect Dis. 2016; 
16: 589.
CR  - 4. Schmader K. Herpes zoster. Clin Geriatr Med. 
2016; 32: 539–353.
CR  - 5. Marin M., et al. Risk factors for herpes zoster 
among adults. Open Forum Infect Dis. 2016; 3:119.
CR  - 6. Kwok TSH., Daneman N., and Lake SL. 
Headache and vision changes in an elderly man with 
rheumatoid arthritis. Int J Rheum Dis. 
2019;22(7):1331-1334.
CR  - 7. Arvin A. Aging, immunity and the varicella zoster 
virus. NEJM. 2005; 352: 2266-7.
CR  - 8. Thomas SL. and Hall AJ. What does 
epidemiology tell us about risk factors for herpes 
zoster? Lancet Infect Dis. 2004; 4: 26-33.
CR  - 9. Vrcek I., Choudhury E. and Durairaj V. Herpes 
Zoster Ophthalmicus: A Review for the Internist. 
Am J Med. 2017;130(1):21–26.
CR  - 10. Hutchinson J. A clinical report on herpes zoster 
ophthalmicus (shingles affecting the forehead and 
nose). Trans Am Ophthalmol Soc. 1942; 40:390-
439.
CR  - 11. Sjaastad O. et al. Shortlasting unilateral 
neuralgiform headache attacks with conjunctival 
injection, tearing, sweating, and rhinorrhea. 
Cephalalgia 1989; 9:147–156.
CR  - 12. Akpinar ÇK. ve ark. Herpes Zoster 
Ophthalmicus That Mimics the SUNCT Syndrome. 
Noro Psikiyatr Ars. 2016; 53(2):184-185.
CR  - 13. Sengupta, S. Cutaneous herpes zoster. Curr 
Infect Dis Rep. 2013; 15: 432–439.
CR  - 14. Woznowski M. et al. Fulminant staphylococcus 
lugdunensis septicaemia following a pelvic
varicella-zoster virus infection in an immune-
deficient patient: a case report. Eur J Med Res. 2010; 
15: 410–414.
CR  - 15. Sanjay S. et all. Complete unilateral 
ophthalmoplegia in herpes zoster ophthalmicus. J 
Neuroophthalmol. 2009; 29(4): 325-337.
CR  - 16. Werner RN, et al. European consensus-based 
(S2k) Guideline on the Management of Herpes 
Zoster - guided by the European Dermatology 
Forum (EDF) in cooperation with the European 
Academy of Dermatology and Venereology 
(EADV), Part 2: Treatment. J Eur Acad Dermatol 
Venereol. 2017;31(1):20-29.
CR  - 17. Tran KD., et al. Epidemiology of herpes zoster 
ophthalmicus: recurrence and chronicity. 
Ophthalmology. 2016; 123: 1469–1475.
CR  - 18. Hales, C.M., et al. Update on recommendations 
for use of herpes zoster vaccine. MMWR Morb 
Mortal Wkly Rep. 2014; 63: 729–731.
UR  - https://dergipark.org.tr/tr/pub/mjwbs/issue//521477
L1  - https://dergipark.org.tr/tr/download/article-file/797121
ER  -